The GMT, a crucial process in glial tumor progression, is characterized by the reduction of glial markers (GFAP, which is also used as an astrocytic lineage-specific marker [13]) in exchange for increased expression of mesenchymal markers, such as vimentin [14]. The gene discussed is GFAP; the disease is glioma.